HYDROPHOBIC MEDICINES IN NANOPARTICLES MADE OF HIGH-DENSITY LIPOPROTEIN (HDL) WITH AN ORGANIC CORE
DE602021055052T2Active Publication Date: 2026-05-27CITY OF HOPE +1
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- DE602021055052
- Authority / Receiving Office
- DE · DE
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2020-10-23
- Filing Date
- 2021-10-22
- Publication Date
- 2026-05-27
- Estimated Expiration
- 2041-10-22
AI Technical Summary
Technical Problem
Hydrophobic drugs like F7 face challenges with formulation, biodistribution, bioavailability, and delivery to tumor tissues due to their hydrophobic nature, leading to limited therapeutic efficacy and increased side effects when encapsulated in lipid vesicles.
Method used
Synthesis of HDL-like nanoparticles with a lipid-conjugated organic core scaffold that encapsulates hydrophobic drugs, mimicking human HDLs in size, shape, and charge, and targets tumor cells through scavenger receptor type B1, using apolipoprotein A-I for delivery.
Benefits of technology
The HDL-like nanoparticles efficiently deliver hydrophobic drugs to cancer cells, reducing tumor burden with similar cytotoxicity profiles to free drugs while minimizing side effects and improving drug loading.
✦ Generated by Eureka AI based on patent content.
Need to check novelty before this filing date? Find Prior Art
No text content released.